<DOC>
	<DOC>NCT01814709</DOC>
	<brief_summary>This open-label, two-arm, drug interaction study will investigate the effect of co-administration of rifampin or itraconazole on the pharmacokinetics of GDC-0032 in healthy volunteers. In Arm A, volunteers will receive GDC-0032 and rifampin; in Arm B, volunteers will receive GDC-0032 and itraconazole. The anticipated time on study treatment is approximately 30 days.</brief_summary>
	<brief_title>A Drug Interaction Study of GDC-0032 Co-administered With Rifampin or Itraconazole in Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Itraconazole</mesh_term>
	<mesh_term>Hydroxyitraconazole</mesh_term>
	<mesh_term>Rifampin</mesh_term>
	<criteria>Female volunteers will be nonpregnant, nonlactating, and either postmenopausal for at least 1 year or surgically sterile Male volunteers will either be sterile, or agree to use adequate methods of contraception Body mass index (BMI) range 18 to 32 kg/m2, inclusive No clinically significant findings from medical history, physical examination, 12lead ECG, vital signs; and clinical laboratory evaluations Negative hepatitis B virus, hepatitis C virus and negative HIV antibody screens Significant history or clinical manifestation of any significant metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, or psychiatric disorder History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance History of stomach or intestinal surgery or resection that would alter absorption and/or excretion of orally administered study drugs History of alcoholism or drug addiction within 1 year prior to Checkin History of chronic proton pump inhibitor (PPI) use within 6 months of Checkin, or use of PPIs, H2receptor antagonists, or antacids within 1 month prior to Checkin and during the entire study Clinically significant history of liver disease, including viral or other hepatitis, current alcohol abuse, or cirrhosis History type 1 or 2 diabetes and/or elevated fasting glucose at baseline Malabsorption syndrome or other condition that would interfere with enteral absorption Use of any tobacco or nicotine containing products Participation in any other investigational study drug or biologic agent trial in which receipt of an investigational study drug occurred within 5 halflives or 30 days, whichever is longer to Checkin and during the entire study duration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>